PHILADELPHIA–(BUSINESS WIRE)–Virion Therapeutics, LLC, a clinical-stage biotechnology company, developing T cell-based immunotherapies that contain checkpoint modifiers, today announced that an abstract reporting long-term follow-up data of VRON-0200, its novel, first-in-class, immunotherapy for HBV Functional Cure, has been selected for a late-breaking oral presentation at The Liver Meeting® 2026, the annual meeting of the American Association for the Study of Liver Diseases (AASLD), to be h
